Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7825MR)

This product GTTS-WQ7825MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7825MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13053MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ4375MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ13868MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ11105MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ5694MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ2336MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ2502MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ9011MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW